(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 4.04% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Johnson & Johnson's revenue in 2025 is $90,627,000,000.On average, 7 Wall Street analysts forecast JNJ's revenue for 2025 to be $224,971,724,470,403, with the lowest JNJ revenue forecast at $224,831,968,565,661, and the highest JNJ revenue forecast at $225,160,417,821,024. On average, 7 Wall Street analysts forecast JNJ's revenue for 2026 to be $234,559,018,069,137, with the lowest JNJ revenue forecast at $232,695,941,567,791, and the highest JNJ revenue forecast at $235,884,750,818,040.
In 2027, JNJ is forecast to generate $246,259,629,028,051 in revenue, with the lowest revenue forecast at $244,299,486,836,808 and the highest revenue forecast at $249,053,547,770,136.